Metronomic cyclophosphamide induces regulatory T cells depletion and PSA specific T cells reactivation in patients with biochemical recurrent prostate cancer.

Fiche publication

Date publication

novembre 2019

Journal

International journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Pr BORG Christophe , Mme JACQUIN Marion , Mme LAHEURTE Caroline , Dr THIERY-VUILLEMIN Antoine , Dr MOUILLET Guillaume

Tous les auteurs :
Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31749145

Résumé

Biochemical recurrence (BCR) occurs in up to 40% of prostate cancer patients after prostatectomy. In this study, we performed an immune monitoring study in 20 prostate cancer patients with BCR previously treated with metronomic cyclophosphamide (mCTX). We observed a decrease of regulatory T cells (Tregs) from 2 months and this was more pronounced after 6 months of mCTX treatment. This drop of Tregs was associated with increased level of activated HLADR CD45R0 T cells in peripheral blood. Furthermore, a reactivation of Th1 polarized anti-PSA T cell response was detected in BCR patients treated with mCTX. However, dendritic cell subsets counts and activation were not influenced by the treatment. In clinical setting, we found that PSA level control was observed in 82% (9/11) of patients with a significant diminution of Tregs after mCTX compared to 33% (3/9) in patients without Tregs decrease. In addition, 30% (6/20) of patients previously treated with mCTX remained free for androgen deprivation therapy. In conclusion, Tregs diminution and immune activation associated with PSA level control occurred after mCTX in prostate cancer patients with BCR. This article is protected by copyright. All rights reserved.